within Pharmacolibrary.Drugs.ATC.N;

model N06AX13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Medifoxamine is an atypical antidepressant that was previously used primarily in France and some other countries. It functions mainly as a serotonin-norepinephrine reuptake inhibitor (SNRI) as well as a 5-HT2 receptor antagonist. It is no longer marketed or approved for therapeutic use due to concerns about adverse effects, including hepatotoxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult based on known properties of similar SNRIs; no original human PK studies publicly available.</p><h4>References</h4><ol><li><p>Gainsborough, N, et al., &amp; Jackson, SH (1994). The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers. <i>European journal of clinical pharmacology</i> 46(2) 163–166. DOI:<a href=&quot;https://doi.org/10.1007/BF00199882&quot;>10.1007/BF00199882</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8039537/&quot;>https://pubmed.ncbi.nlm.nih.gov/8039537</a></p></li><li><p>Saleh, S, et al., &amp; Turner, P (1990). Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans. <i>British journal of clinical pharmacology</i> 30(4) 621–624. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1990.tb03823.x&quot;>10.1111/j.1365-2125.1990.tb03823.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2291875/&quot;>https://pubmed.ncbi.nlm.nih.gov/2291875</a></p></li><li><p>Saleh, S, et al., &amp; Turner, P (1990). Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers. <i>European journal of clinical pharmacology</i> 39(2) 169–171. DOI:<a href=&quot;https://doi.org/10.1007/BF00280053&quot;>10.1007/BF00280053</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2253668/&quot;>https://pubmed.ncbi.nlm.nih.gov/2253668</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AX13;
